New hope for Hard-to-Treat cancers: first human trial launches

NCT ID NCT06403436

First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 24 times

Summary

This study tests a new drug called TT125-802 in about 50 adults with advanced solid tumors (like lung cancer) that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the best dose. Researchers will also look at whether the drug can shrink tumors or slow cancer growth.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Centre Hospitalier Universitaire Vaudois

    Lausanne, 1890, Switzerland

  • Ente Ospedaliero Cantonale

    Bellinzona, 6500, Switzerland

  • NEXT Oncology Barcelona

    Barcelona, 08023, Spain

  • NEXT Oncology Madrid

    Madrid, 28223, Spain

  • NEXT Oncology Virginia

    Fairfax, Virginia, 22031, United States

  • Sarah Cannon Research Institute Oncology Partners

    Nashville, Tennessee, 37203, United States

  • Vall d'Hebron Institute of Oncology

    Barcelona, 08035, Spain

Conditions

Explore the condition pages connected to this study.